Anti-HIV Drug Design
- HIV-1 protease, or PR, is essential to the replication of human immunodeficiency virus-1, and is consequently the target of major drug design programs worldwide. Our computational work is part of a closely-knit Program, involving several other laboratories, to develop both novel and mature tools to aid in the drug design cycle for anti-retroviral agents. The program consists of the following integrated parts:
- Computational methods for docking active site ligands (inhibitors), and for elaboration and refined design of inhibitor lead compounds;
- Design and chemical synthesis of retroviral protease inhibitors using new chemical approaches;
- X-ray crystallographic studies of the feline immunodeficiency virus (FIV PR) and inhibitor complexes;
- Molecular biology/virology of the FIV system.
- Our laboratory is exploring a new paradigm in distributed computing, by launching www.FightAIDSatHome.org in September 2000. Tens of thousands of people around the world run AutoDock on HIV Protease on their personal computers. The goal? To design better protease inhibitors that are more robust in the face of HIV resistance.